Table 2

Allele and genotype frequencies of rs1337185, rs5275, rs5277, rs7575934, rs3213718 and rs162509 in controls and cases including four subgroups

SNPsGenotype (%)Allele (%)
rs1337185 CC CG GG p(χ2) p* C G p(χ2) p* OR (95% CI) HWE
Controls (n=400)4 (1.0)62 (15.5)334 (83.5)0.00170 (8.8)730 (91.2)0.0011.72 (1.25 to 2.34)0.55
Cases (n=428)5 (1.2)111 (25.9)312 (72.9)121 (14.1)735 (85.9)0.15
Subgroup 1 (n=156)2 (1.3)42 (26.9)112 (71.8)0.0070.02846 (14.7)266 (85.3)0.0030.0121.08 (1.21 to 2.68)0.37
Subgroup 2 (n=84)1 (1.2)18 (21.4)65 (77.4)0.4031.020 (11.9)148 (88.1)0.2010.8041.22 (0.74 to 2.02)0.84
Subgroup 3 (n=141)2 (1.4)40 (28.4)99 (70.2)0.0030.01244 (15.6)238 (84.4)0.0010.0041.92 (1.29 to 2.89)0.35
Subgroup 4 (n=47)0 (0.0)11 (23.4)36 (76.6)0.3131.011 (11.7)83 (88.3)0.3461.01.24 (0.64 to 2.40)0.36
rs5275 CC CT TT p(χ 2) p* C T p(χ 2) p* OR (95% CI) HWE
Controls (n=400)9 (2.3)112 (28.0)279 (69.7)0.131130 (16.3)670 (83.7)0.0940.81 (0.63 to 1.04)0.56
Cases (n=428)20 (4.7)126 (29.4)282 (65.9)166 (19.4)690 (80.6)0.22
Subgroup 1 (n=156)7 (4.5)51 (32.7)98 (62.8)0.1660.66465 (20.8)247 (79.2)0.0700.280.74 (0.53 to 1.03)0.91
Subgroup 2 (n=84)5 (6.0)17 (20.2)62 (73.8)0.0810.32427 (16.1)141 (83.9)0.9541.01.01 (0.63 to 1.59)0.02
Subgroup 3 (n=141)6 (4.3)47 (33.3)88 (62.4)0.1870.74859 (20.9)223 (79.1)0.0760.3040.73 (0.52 to 1.03)0.93
Subgroup 4 (n=47)2 (4.3)11 (23.4)34 (72.3)0.5911.015 (16.0)79 (84.0)0.9411.01.02 (0.57 to 1.83)0.38
rs5277 CC CG GG p(χ 2) p* C G p(χ 2) p* OR (95% CI) HWE
Controls (n=400)3 (0.8)38 (9.5)359 (89.8)0.29444 (5.5)756 (94.5)0.1230.73 (0.49 to 1.09)0.23
Cases (n=428)4 (0.9)55 (12.9)369 (86.2)63 (7.4)793 (92.6)0.08
Subgroup 1 (n=156)2 (1.3)18 (11.5)136 (87.2)0.6371.022 (7.1)290 (92.9)0.3251.00.78 (0.45 to 1.30)0.13
Subgroup 2 (n=84)0 (0.0)12 (14.3)72 (85.7)0.2140.85612 (7.6)156 (92.4)0.2791.00.72 (0.37 to 1.34)0.44
Subgroup 3 (n=141)2 (1.4)17 (12.1)122 (86.5)0.5231.021 (7.4)261 (92.4)0.2360.9440.72 (0.42 to 1.24)0.13
Subgroup 4 (n=47)0 (0.0)8 (17.0)39 (83.0)0.2360.9448 (8.5)86 (91.5)0.2380.9520.63 (0.29 to 1.37)0.52
rs7575934 CC CT TT p(χ 2) p* C T p(χ 2) p* OR (95% CI) HWE
Controls (n=400)257 (64.2)126 (31.5)17 (4.3)0.320640 (80.0)160 (20.0)0.2061.16 (0.92 to 1.47)0.75
Cases (n=428)263 (61.4)137 (32.0)28 (6.5)663 (77.5)193 (22.5)0.08
Subgroup 1 (n=156)94 (60.3)49 (31.4)13 (8.3)0.2521.0237 (76.6)75 (23.4)0.2110.8441.22 (0.89 to 1.67)0.12
Subgroup 2 (n=84)52 (61.9)24 (28.6)8 (9.5)0.1360.544128 (76.2)40 (23.8)0.2671.01.25 (0.84 to 1.86)0.05
Subgroup 3 (n=141)92 (65.2)45 (32.0)4 (2.8)0.7561.0229 (81.2)53 (18.8)0.6611.00.93 (0.66 to 1.31)0.58
Subgroup 4 (n=47)25 (53.2)19 (40.4)3 (6.4)0.3201.069 (73.4)25 (26.6)0.1350.541.45 (0.89 to 2.36)0.80
rs3213718 CC CT TT p(χ 2) p* C T p(χ 2) p* OR (95% CI) HWE
Controls (n=400)285 (71.3)101 (25.2)14 (3.5)0.395671 (83.9)129 (16.1)0.2331.17 (0.90 to 1.51)0.18
Cases (n=428)294 (68.7)111 (25.9)23 (5.4)699 (81.7)157 (18.3)0.01
Subgroup 1 (n=156)121 (77.6)28 (17.9)7 (4.5)0.1750.7270 (86.5)42 (13.5)0.2691.00.81 (0.56 to 1.18)0.01
Subgroup 2 (n=84)52 (61.9)28 (33.3)4 (4.8)0.2380.952132 (78.6)36 (21.4)0.0960.3841.42 (0.94 to 2.15)0.92
Subgroup 3 (n=141)92 (65.2)40 (28.4)9 (6.4)0.2270.908224 (79.4)58 (20.6)0.0890.3561.35 (0.95 to 1.90)0.11
Subgroup 4 (n=47)29 (61.7)15 (31.9)3 (6.4)0.3351.073 (77.7)21 (22.3)0.1270.5081.50 (0.89 to 2.52)0.58
rs162509 CC CG GG p(χ 2) p* C G p(χ 2) p* OR (95% CI) HWE
Controls (n=400)72 (18.0)186 (46.5)142 (35.5)0.007330 (41.3)470 (58.7)0.0011.38 (1.13 to 1.69)0.41
Cases (n=428)52 (12.1)184 (43.0)192 (44.9)288 (33.6)568 (66.4)0.44
Subgroup 1 (n=156)17 (10.9)62 (39.7)77 (49.4)0.0060.02496 (30.8)216 (69.2)0.0010.0041.58 (1.20 to 2.09)0.40
Subgroup 2 (n=84)8 (9.5)43 (51.2)33 (39.3)0.1640.65659 (35.1)109 (64.9)0.1410.5641.30 (0.92 to 1.83)0.25
Subgroup 3 (n=141)22 (15.6)62 (44.0)57 (40.4)0.5551.0106 (37.6)176 (62.4)0.2811.01.17 (0.88 to 1.54)0.45
Subgroup 4 (n=47)5 (10.6)17 (36.2)25 (53.2)0.0500.227 (28.7)67 (71.3)0.0190.0761.72 (1.09 to 2.78)0.42
  • p*, Bonferroni-corrected p value.

  • Subgroup 1, patients with disc herniation only.

  • Subgroup 2, patients with discopathies and/or osteochondrosis associated with disc herniation.

  • Subgroup 3, patients with stenosis, spondylolisthesis or both.

  • Subgroup 4, patients with degenerative scoliosis.

  • HWE, Hardy-Weinberg equilibrium; SNPs, single nucleotide polymorphisms.